

Sean Moran

Mr. Moran is a 26-year-old regular operator's license holder in Massachusetts. He has a history of epilepsy and has been seizure free since 2008. He takes anti-seizure medication with the dosage and frequency remaining the same since 2015. His physician states that he is supportive of Mr. Moran receiving an exemption.

John Picken

Mr. Picken is a 73-year-old class D license holder in Utah. He has a history of stroke aborted by tissue plasminogen activator and has been seizure free since 2021. He does not take anti-seizure medication. His physician states that he is supportive of Mr. Picken receiving an exemption.

Neil Southern

Mr. Southern is a 63-year-old class R license holder in Colorado. He has a history of epilepsy and has been seizure free since 2013. He takes anti-seizure medication with the dosage and frequency remaining the same since 2013. His physician states that he is supportive of Mr. Southern receiving an exemption.

Daniel Verduzco

Mr. Verduzco is a 30-year-old class C license holder in California. He has a history of a single seizure and has been seizure free since 2016. He takes anti-seizure medication with the dosage and frequency remaining the same since 2016. His physician states that he is supportive of Mr. Verduzco receiving an exemption.

Charles Vicars

Mr. Vicars is a 66-year-old class A license holder in Virginia. He has a history of epilepsy and has been seizure free since 1990. He takes anti-seizure medication with the dosage and frequency remaining the same since 2019. His physician states that he is supportive of Mr. Vicars receiving an exemption.

Karl Wilson, Jr.

Mr. Wilson is a 41-year-old class A license holder in Georgia. He has a history of seizures and has been seizure free since 2014. He takes anti-seizure medication with the dosage and frequency remaining the same since 2019. His physician states that he is supportive of Mr. Wilson receiving an exemption.

IV. Request for Comments

In accordance with 49 U.S.C. 31136(e) and 31315(b), FMCSA requests public comment from all interested persons on

the exemption petitions described in this notice. We will consider all comments received before the close of business on the closing date indicated under the **DATES** section of the notice.

Larry W. Minor,

Associate Administrator for Policy.

[FR Doc. 2022-10350 Filed 5-12-22; 8:45 am]

BILLING CODE 4910-EX-P

DEPARTMENT OF TRANSPORTATION**Federal Motor Carrier Safety Administration**

[Docket No. FMCSA-2013-0108; FMCSA-2013-0442; FMCSA-2013-0443; FMCSA-2014-0381; FMCSA-2015-0115; FMCSA-2015-0116; FMCSA-2015-0119; FMCSA-2015-0320; FMCSA-2015-0321; FMCSA-2017-0181; FMCSA-2017-0253; FMCSA-2017-0254; FMCSA-2018-0050; FMCSA-2018-0051; FMCSA-2019-0030; FMCSA-2019-0034; FMCSA-2019-0036; FMCSA-2019-0206; FMCSA-2019-0211; FMCSA-2019-0212; FMCSA-2020-0045; FMCSA-2020-0046]

Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).

ACTION: Notice of renewal of exemptions; request for comments.

SUMMARY: FMCSA announces its decision to renew exemptions for 32 individuals from the requirement in the Federal Motor Carrier Safety Regulations (FMCSRs) that interstate commercial motor vehicle (CMV) drivers have "no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV." The exemptions enable these individuals who have had one or more seizures and are taking anti-seizure medication to continue to operate CMVs in interstate commerce.

DATES: Each group of renewed exemptions were applicable on the dates stated in the discussions below and will expire on the dates stated in the discussions below. Comments must be received on or before June 13, 2022.

ADDRESSES: You may submit comments identified by the Federal Docket Management System (FDMS) Docket No. FMCSA-2013-0108, Docket No. FMCSA-2013-0442, Docket No. FMCSA-2013-0443, Docket No. FMCSA-2014-0381, Docket No. FMCSA-2015-0115, Docket No. FMCSA-2015-0116, Docket No.

FMCSA-2015-0119, Docket No. FMCSA-2015-0320, Docket No. FMCSA-2015-0321, Docket No. FMCSA-2017-0181, Docket No. FMCSA-2017-0253, Docket No. FMCSA-2017-0254, Docket No. FMCSA-2018-0050, Docket No. FMCSA-2018-0051, Docket No. FMCSA-2019-0030, Docket No. FMCSA-2019-0034, Docket No. FMCSA-2019-0036, Docket No. FMCSA-2019-0206, Docket No. FMCSA-2019-0211, Docket No. FMCSA-2019-0212, Docket No. FMCSA-2020-0045, or Docket No. FMCSA-2020-0046 using any of the following methods:

Federal eRulemaking Portal: Go to www.regulations.gov/, insert the docket number, FMCSA-2013-0108, FMCSA-2013-0442, FMCSA-2013-0443, FMCSA-2014-0381, FMCSA-2015-0115, FMCSA-2015-0116, FMCSA-2015-0119, FMCSA-2015-0320, FMCSA-2015-0321, FMCSA-2017-0181, FMCSA-2017-0253, FMCSA-2017-0254, FMCSA-2018-0050, FMCSA-2018-0051, FMCSA-2019-0030, FMCSA-2019-0034, FMCSA-2019-0036, FMCSA-2019-0206, FMCSA-2019-0211, FMCSA-2019-0212, FMCSA-2020-0045, or FMCSA-2020-0046 in the keyword box, and click "Search." Next, sort the results by "Posted (Newer-Older)," choose the first notice listed, and click on the "Comment" button. Follow the online instructions for submitting comments.

- *Mail:* Dockets Operations; U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Room W12-140, Washington, DC 20590-0001.

- *Hand Delivery:* West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC 20590-0001 between 9 a.m. and 5 p.m., ET, Monday through Friday, except Federal Holidays.

- *Fax:* (202) 493-2251.

To avoid duplication, please use only one of these four methods. See the "Public Participation" portion of the **SUPPLEMENTARY INFORMATION** section for instructions on submitting comments.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief, Medical Programs Division, (202) 366-4001, fmcsamedical@dot.gov, FMCSA, DOT, 1200 New Jersey Avenue SE, Room W64-224, Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m., ET, Monday through Friday, except Federal holidays. If you have questions regarding viewing or submitting material to the docket, contact Dockets Operations, (202) 366-9826.

SUPPLEMENTARY INFORMATION:**I. Public Participation****A. Submitting Comments**

If you submit a comment, please include the docket number for this notice (Docket No. FMCSA–2013–0108, Docket No. FMCSA–2013–0442, Docket No. FMCSA–2013–0443, Docket No. FMCSA–2014–0381, Docket No. FMCSA–2015–0115, Docket No. FMCSA–2015–0116, Docket No. FMCSA–2015–0119, Docket No. FMCSA–2015–0320, Docket No. FMCSA–2015–0321, Docket No. FMCSA–2017–0181, Docket No. FMCSA–2017–0253, Docket No. FMCSA–2017–0254, Docket No. FMCSA–2018–0050, Docket No. FMCSA–2018–0051, Docket No. FMCSA–2019–0030, Docket No. FMCSA–2019–0034, Docket No. FMCSA–2019–0036, Docket No. FMCSA–2019–0206, Docket No. FMCSA–2019–0211, Docket No. FMCSA–2019–0212, Docket No. FMCSA–2020–0045, or Docket No. FMCSA–2020–0046), indicate the specific section of this document to which each comment applies, and provide a reason for each suggestion or recommendation. You may submit your comments and material online or by fax, mail, or hand delivery, but please use only one of these means. FMCSA recommends that you include your name and a mailing address, an email address, or a phone number in the body of your document so that FMCSA can contact you if there are questions regarding your submission.

To submit your comment online, go to www.regulations.gov/, insert the docket number, FMCSA–2013–0108, FMCSA–2013–0442, FMCSA–2013–0443, FMCSA–2014–0381, FMCSA–2015–0115, FMCSA–2015–0116, FMCSA–2015–0119, FMCSA–2015–0320, FMCSA–2015–0321, FMCSA–2017–0181, FMCSA–2017–0253, FMCSA–2017–0254, FMCSA–2018–0050, FMCSA–2018–0051, FMCSA–2019–0030, FMCSA–2019–0034, FMCSA–2019–0036, FMCSA–2019–0206, FMCSA–2019–0211, FMCSA–2019–0212, FMCSA–2020–0045, or FMCSA–2020–0046 in the keyword box, and click “Search.” Next, sort the results by “Posted (Newer-Older),” choose the first notice listed, click the “Comment” button, and type your comment into the text box on the following screen. Choose whether you are submitting your comment as an individual or on behalf of a third party and then submit.

If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8½ by

11 inches, suitable for copying and electronic filing. If you submit comments by mail and would like to know that they reached the facility, please enclose a stamped, self-addressed postcard or envelope.

FMCSA will consider all comments and material received during the comment period.

B. Viewing Comments

To view comments go to www.regulations.gov. Insert the docket number, FMCSA–2013–0108, FMCSA–2013–0442, FMCSA–2013–0443, FMCSA–2014–0381, FMCSA–2015–0115, FMCSA–2015–0116, FMCSA–2015–0119, FMCSA–2015–0320, FMCSA–2015–0321, FMCSA–2017–0181, FMCSA–2017–0253, FMCSA–2017–0254, FMCSA–2018–0050, FMCSA–2018–0051, FMCSA–2019–0030, FMCSA–2019–0034, FMCSA–2019–0036, FMCSA–2019–0206, FMCSA–2019–0211, FMCSA–2019–0212, FMCSA–2020–0045, or FMCSA–2020–0046 in the keyword box, and click “Search.” Next, sort the results by “Posted (Newer-Older),” choose the first notice listed, and click “Browse Comments.” If you do not have access to the internet, you may view the docket online by visiting Dockets Operations in Room W12–140 on the ground floor of the DOT West Building, 1200 New Jersey Avenue SE, Washington, DC 20590–0001, between 9 a.m. and 5 p.m., ET, Monday through Friday, except Federal holidays. To be sure someone is there to help you, please call (202) 366–9317 or (202) 366–9826 before visiting Dockets Operations.

C. Privacy Act

In accordance with 49 U.S.C. 31315(b)(6), DOT solicits comments from the public on the exemption request. DOT posts these comments, without edit, including any personal information the commenter provides, to www.regulations.gov, as described in the system of records notice (DOT/ALL–14 FDMS), which can be reviewed at www.dot.gov/privacy.

II. Background

Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption from the FMCSRs for no longer than a 5-year period if it finds such exemption would likely achieve a level of safety that is equivalent to, or greater than, the level that would be achieved absent such exemption. The statute also allows the Agency to renew exemptions at the end of the 5-year period. FMCSA grants medical exemptions from the FMCSRs for a 2-year period to align with the maximum

duration of a driver's medical certification.

The physical qualification standard for drivers regarding epilepsy found in 49 CFR 391.41(b)(8) states that a person is physically qualified to drive a CMV if that person has no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause the loss of consciousness or any loss of ability to control a CMV.

In addition to the regulations, FMCSA has published advisory criteria¹ to assist Medical Examiners in determining whether drivers with certain medical conditions are qualified to operate a CMV in interstate commerce.

The 32 individuals listed in this notice have requested renewal of their exemptions from the epilepsy and seizure disorders prohibition in § 391.41(b)(8), in accordance with FMCSA procedures. Accordingly, FMCSA has evaluated these applications for renewal on their merits and decided to extend each exemption for a renewable 2-year period.

III. Request for Comments

Interested parties or organizations possessing information that would otherwise show that any, or all, of these drivers are not currently achieving the statutory level of safety should immediately notify FMCSA. The Agency will evaluate any adverse evidence submitted and, if safety is being compromised or if continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315(b), FMCSA will take immediate steps to revoke the exemption of a driver.

IV. Basis for Renewing Exemptions

In accordance with 49 U.S.C. 31136(e) and 31315(b), each of the 32 applicants has satisfied the renewal conditions for obtaining an exemption from the epilepsy and seizure disorders prohibition. The 32 drivers in this notice remain in good standing with the Agency, have maintained their medical monitoring and have not exhibited any medical issues that would compromise their ability to safely operate a CMV during the previous 2-year exemption period. In addition, for commercial driver's license (CDL) holders, the Commercial Driver's License Information System and the Motor

¹ These criteria may be found in APPENDIX A TO PART 391—MEDICAL ADVISORY CRITERIA, section H. *Epilepsy*: § 391.41(b)(8), paragraphs 3, 4, and 5, which is available on the internet at <https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf>.

Carrier Management Information System are searched for crash and violation data. For non-CDL holders, the Agency reviews the driving records from the State Driver's Licensing Agency. These factors provide an adequate basis for predicting each driver's ability to continue to safely operate a CMV in interstate commerce. Therefore, FMCSA concludes that extending the exemption for each renewal applicant for a period of 2 years is likely to achieve a level of safety equal to that existing without the exemption.

In accordance with 49 U.S.C. 31136(e) and 31315(b), the following groups of drivers received renewed exemptions in the month of May and are discussed below.

As of May 15, 2022, and in accordance with 49 U.S.C. 31136(e) and 31315(b), the following 29 individuals have satisfied the renewal conditions for obtaining an exemption from the epilepsy and seizure disorders prohibition in the FMCSRs for interstate CMV drivers:

William Brown (NC)
 Frank Corino (NJ)
 Barry Dull (OH)
 Robert J. Forney (WI)
 Scott William Gessner (PA)
 Daniel Halstead (NV)
 Aaron Harms (MO)
 Matthew Heinen (MN)
 Logan Hertzler (PA)
 Brian Johnson (MN)
 Preston R. Kanagy (TN)
 Kenneth L. Lewis (NC)
 Larry Lintelman (AK)
 Kevin Market (OH)
 Shane W. Martinek (OK)
 Jeffrey Mills (NC)
 Gary Olsen (MN)
 Randy Pinto (PA)
 Matthew Scarlata (NY)
 Steven Shirley (UT)
 Chad Smith (MA)
 Alvin Strite (PA)
 Jeffrey Totten (KS)
 Paul Vitous (WA)
 Thomas B. Vivirito (PA)
 Mohammad S. Warrad (IA)
 Richard J. Wenner (MN)
 Michael R. Weymouth (NH)
 Dennis R. Zayic (MN)

The drivers were included in docket number FMCSA–2013–0108, FMCSA–2013–0442, FMCSA–2014–0381, FMCSA–2015–0115, FMCSA–2015–0116, FMCSA–2015–0119, FMCSA–2015–0320, FMCSA–2015–0321, FMCSA–2017–0181, FMCSA–2017–0253, FMCSA–2017–0254, FMCSA–2018–0050, FMCSA–2019–0030, FMCSA–2019–0034, FMCSA–2019–0036, FMCSA–2019–0206, FMCSA–2019–0211, FMCSA–2019–0212,

FMCSA–2020–0045, or FMCSA–2020–0046. Their exemptions are applicable as of May 15, 2022 and will expire on May 15, 2024.

As of May 19, 2022, and in accordance with 49 U.S.C. 31136(e) and 31315(b), the following two individuals have satisfied the renewal conditions for obtaining an exemption from the epilepsy and seizure disorders prohibition in the FMCSRs for interstate CMV drivers:

Ronald Hartl (WI) and Michael Miller (WI).

The drivers were included in docket number FMCSA–2013–0443. Their exemptions are applicable as of May 19, 2022 and will expire on May 19, 2024.

As of May 30, 2022, and in accordance with 49 U.S.C. 31136(e) and 31315(b), Nathan Kanouff (GA) has satisfied the renewal conditions for obtaining an exemption from the epilepsy and seizure disorders prohibition in the FMCSRs for interstate CMV drivers.

This driver was included in docket number FMCSA–2018–0051. The exemption is applicable as of May 30, 2022 and will expire on May 30, 2024.

VI. Conditions and Requirements

The exemptions are extended subject to the following conditions: (1) Each driver must remain seizure-free and maintain a stable treatment during the 2-year exemption period; (2) each driver must submit annual reports from their treating physicians attesting to the stability of treatment and that the driver has remained seizure-free; (3) each driver must undergo an annual medical examination by a certified ME, as defined by § 390.5; and (4) each driver must provide a copy of the annual medical certification to the employer for retention in the driver's qualification file, or keep a copy of his/her driver's qualification file if he/she is self-employed. The driver must also have a copy of the exemption when driving, for presentation to a duly authorized Federal, State, or local enforcement official. The exemption will be rescinded if: (1) The person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained before it was granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315(b).

VI. Preemption

During the period the exemption is in effect, no State shall enforce any law or regulation that conflicts with this

exemption with respect to a person operating under the exemption.

VII. Conclusion

Based on its evaluation of the 32 exemption applications, FMCSA renews the exemptions of the aforementioned drivers from the epilepsy and seizure disorders prohibition in § 391.41(b)(8). In accordance with 49 U.S.C. 31136(e) and 31315(b), each exemption will be valid for 2 years unless revoked earlier by FMCSA.

Larry W. Minor,

Associate Administrator for Policy.

[FR Doc. 2022–10277 Filed 5–12–22; 8:45 am]

BILLING CODE 4910–EX–P

DEPARTMENT OF TRANSPORTATION

Federal Railroad Administration

[Docket No. FRA–2022–0031]

Establishment of the Corridor Identification and Development Program

AGENCY: Federal Railroad Administration (FRA), Department of Transportation (DOT).

ACTION: Notice of establishment; request for expressions of interest.

SUMMARY: On November 15, 2021, President Biden signed into law the Infrastructure Investment and Jobs Act, also known as the Bipartisan Infrastructure Law (BIL), which requires the Secretary of Transportation (Secretary) to establish a Corridor Identification and Development program to facilitate the development of intercity passenger rail corridors within 180 days of enactment. In compliance with this directive, by this Notice, FRA is establishing the Corridor Identification and Development program.

ADDRESSES: See the **SUPPLEMENTARY INFORMATION** section for further information regarding submitting expressions of interest to docket number FRA–2022–0031.

FOR FURTHER INFORMATION CONTACT: For further information, please contact Peter Schwartz, Chief, Project Engineering and Transportation Planning Division, by email: PaxRailDev@dot.gov or by telephone: 202–493–6360.

SUPPLEMENTARY INFORMATION:

Table of Contents for Supplementary Information

- I. Executive Summary
- II. Federal Role in Intercity Passenger Rail Service Development
- III. Statutory Overview